2022
T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation
Borges T, Abarzua P, Gassen R, Kollar B, Lima-Filho M, Aoyama B, Gluhova D, Clark R, Islam S, Pomahac B, Murphy G, Lian C, Talbot S, Riella L. T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation. Cell Reports Medicine 2022, 3: 100559. PMID: 35492875, PMCID: PMC9040185, DOI: 10.1016/j.xcrm.2022.100559.Peer-Reviewed Original ResearchConceptsLimb transplantationTransplant recipientsSkin antigen-presenting cellsSolid organ transplant recipientsAccelerated graft rejectionOrgan transplant recipientsSkin transplantation modelAntigen-presenting cellsLife-changing procedureImmunosuppressive approachesTh17 cellsGraft rejectionGreater immunogenicityCell infiltrationSkin biopsiesTransplantation modelSkin xenograftsChemokine CCL18Immune moleculesTransplantationCCL18RecipientsMolecular characterizationChemokinesCCR8 receptor
2020
Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsRatsSwineTacrolimusTreatment OutcomeVascularized Composite AllotransplantationConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategies
2019
The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation
Haug V, Kollar B, Obed D, Kiwanuka H, Turk M, Wo L, Tasigiorgos S, Kueckelhaus M, Riella L, Pomahac B. The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation. Facial Plastic Surgery & Aesthetic Medicine 2019, 21: 278-285. PMID: 30998810, PMCID: PMC6646986, DOI: 10.1001/jamafacial.2019.0076.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiopsyDiagnosis, DifferentialErythemaExanthemaFacial TransplantationFemaleFollow-Up StudiesGraft RejectionHumansImmunosuppressive AgentsMaleMiddle AgedConceptsAcute rejectionSubtherapeutic tacrolimus levelsClinical signsRejection episodesImmunosuppressive therapySubclinical rejectionTacrolimus levelsMedical recordsOdds ratioFacial transplantationDiagnostic valueSignificant associationSingle-center cohort studyLate rejection episodesProtocol skin biopsiesSecond posttransplant yearSymptoms of rejectionTacrolimus blood levelsSecond postoperative yearReliable clinical signFull facial transplantationPostoperative yearPosttransplant yearYears posttransplantationAllograft rejection
2018
Chronic rejection of human face allografts
Krezdorn N, Lian C, Wells M, Wo L, Tasigiorgos S, Xu S, Borges T, Frierson R, Stanek E, Riella L, Pomahac B, Murphy G. Chronic rejection of human face allografts. American Journal Of Transplantation 2018, 19: 1168-1177. PMID: 30312535, PMCID: PMC6433509, DOI: 10.1111/ajt.15143.Peer-Reviewed Original ResearchMeSH KeywordsAdultChronic DiseaseComposite Tissue AllograftsFacial TransplantationFemaleGene Expression ProfilingGraft RejectionHumansImmunosuppressive AgentsMaleMiddle AgedConceptsChronic rejectionComposite allograftsAutoimmune cutaneous disordersImmune-mediated changesLymphocyte-mediated cytotoxicityC-fosSevere facial disfigurementType IAcute rejectionSurveillance biopsiesIatrogenic immunosuppressionVascular ectasiaFollicular pluggingSystemic sclerosisHistopathologic evidenceClinical manifestationsPreventative therapyCutaneous disordersGraft durabilityFace allograftNasal mucosaPathologic changesPathologic alterationsEpidermal thinningSclerotic zoneInnovations in reconstructive microsurgery: Reconstructive transplantation
Kollar B, Tasigiorgos S, Dorante M, Carty M, Talbot S, Pomahac B. Innovations in reconstructive microsurgery: Reconstructive transplantation. Journal Of Surgical Oncology 2018, 118: 800-806. PMID: 30098294, DOI: 10.1002/jso.25147.Peer-Reviewed Original ResearchMeSH KeywordsForecastingGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsMicrosurgeryOrgan TransplantationConceptsReconstructive transplantationViable reconstructive optionPediatric transplantsUpper extremityLower extremitiesAbdominal wallReconstructive optionsAdditional proceduresReconstructive microsurgeryTransplantationFace transplantTransplantPresent review articleExtremitiesReview articlePatientsUterusNeck
2017
Seasonal Variability Precipitating Hand Transplant Rejection?
Lopdrup R, Turk M, Win T, Marty F, Molway D, Tullius S, Pomahac B, Talbot S. Seasonal Variability Precipitating Hand Transplant Rejection? Transplantation 2017, 101: e313. PMID: 28930103, DOI: 10.1097/tp.0000000000001877.Peer-Reviewed Original ResearchRole of Facial Vascularized Composite Allotransplantation in Burn Patients
Bharadia D, Sinha I, Pomahac B. Role of Facial Vascularized Composite Allotransplantation in Burn Patients. Clinics In Plastic Surgery 2017, 44: 857-864. PMID: 28888310, DOI: 10.1016/j.cps.2017.05.017.Peer-Reviewed Original ResearchMeSH KeywordsBurnsComposite Tissue AllograftsEstheticsFacial InjuriesFacial TransplantationHumansImmunosuppressive AgentsPatient SelectionConceptsComposite allotransplantationFacial Vascularized Composite AllotransplantationExtensive burn injuriesRisk of rejectionVascularized Composite AllotransplantationQuality of lifeLifelong regimenVCA patientsImmunosuppression medicationsPowerful reconstructive toolsBurn patientsTreatment optionsSurgical techniqueBurn injuryReconstructive surgeryPatientsReconstructive toolFace transplantationAllotransplantationImproved qualityFacial formImmunosuppressionMedicationsRegimenSurgery
2016
Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation
Krezdorn N, Murakami N, Pomahac B, Riella L. Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation. American Journal Of Transplantation 2016, 16: 3305-3307. PMID: 27457067, PMCID: PMC5087655, DOI: 10.1111/ajt.13977.Peer-Reviewed Original Research
2015
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration
Kueckelhaus M, Fischer S, Seyda M, Bueno E, Aycart M, Alhefzi M, ElKhal A, Pomahac B, Tullius S. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transplant International 2015, 29: 655-662. PMID: 26265179, PMCID: PMC4785085, DOI: 10.1111/tri.12652.Peer-Reviewed Original ResearchConceptsAcute rejectionImproved long-term graft outcomesLong-term graft outcomeChronic allograft deteriorationCytomegalovirus infection statusGraft preservation techniquesUpper extremity transplantationUpper extremity transplantsAntibody-mediated rejectionGood midterm resultsSpecific treatment strategiesAllograft deteriorationChronic rejectionClinical VCAVCA graftsGraft outcomeImmunosuppressive strategiesLocal immunosuppressionMidterm resultsExtremity transplantationCell-based therapiesHLA matchingTolerance inductionTreatment strategiesUS CentersInitial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation
Diaz-Siso J, Fischer S, Sisk G, Bueno E, Kueckelhaus M, Talbot S, Carty M, Treister N, Marty F, Milford E, Pomahac B, Tullius S. Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation. American Journal Of Transplantation 2015, 15: 1421-1431. PMID: 25777324, DOI: 10.1111/ajt.13103.Peer-Reviewed Original ResearchConceptsAcute rejectionVCA recipientsMaintenance immunosuppressionSteroid-resistant acute rejectionLate acute rejectionSolid organ transplantationComposite tissue allotransplantationMaintenance steroidsTopical immunosuppressionCurrent immunosuppressionSteroid withdrawalBolus treatmentOrgan transplantationLow doseImmunosuppressionTissue allotransplantationInitial experienceFurther experienceSteroidsRecipientsTacrolimusPatientsTreatmentMonthsLow levelsManagement of Steroid-resistant Late Acute Cellular Rejection Following Face Transplantation: A Case Report
Janis J, MacKenzie K, Wright S, Pomahac B, Lu C, Susa J, Wada S, Vazquez M, Chong T, Tullius S. Management of Steroid-resistant Late Acute Cellular Rejection Following Face Transplantation: A Case Report. Transplantation Proceedings 2015, 47: 223-225. PMID: 25645808, DOI: 10.1016/j.transproceed.2014.09.152.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntilymphocyte SerumBurnsFacial InjuriesFacial TransplantationGraft RejectionHumansImmunosuppressive AgentsMale
2013
The Case for Lower Extremity Allotransplantation
Carty M, Zuker R, Cavadas P, Pribaz J, Talbot S, Pomahac B. The Case for Lower Extremity Allotransplantation. Plastic & Reconstructive Surgery 2013, 131: 1272-1277. PMID: 23416434, DOI: 10.1097/prs.0b013e31828bd1a5.Peer-Reviewed Original Research